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Airway mucus is a complex airway secretion whose primary function as part of the mucociliary transport mechanism is to to serve as renewable and
transportable barrier against inhaled particulates and toxic agents. The rheologic properties necessary for this function are imparted by glycoproteins,
or mucins. Some respiratory disease states, e.g., asthma, cystic fibrosis, and bronchitis, are characterized by quantitative and qualitative changes in
mucus biosynthesis that contribute to pulmonary pathology. Similar alterations in various aspects of mucin biochemistry and biophysics, leading to
mucus hypersecretion and altered mucus rheology, result from inhalation of certain air pollutants, such as ozone, sulfur dioxide, nitrogen dioxide,
and cigarette smoke. The consequences of these pollutant-induced alterations in mucus biology are discussed in the context of pulmonary patho-
physiology and toxicology. - Environ Health Perspect 102(Suppl 2):89-103 (1994).
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Introduction
The lung is a unique organ in it consists of
a very large epithelial surface that is contin-
uously exposed to the outside world.
Unlike a similarly exposed epithelial sur-
face, the skin, the lung cannot make use of
multiple layers of relatively impermeable
cells as a barrier to harmful substances in
the outside environment. This is because
the function ofthe lung, i.e., gas exchange,
demands that there be a minimal thickness
of gas-permeable cell membranes between
the airspace and the blood. Instead, the
lung uses specialized secretions produced
by the airways to provide a renewable and
transportable protective layer to interact
with, neutralize and remove inhaled toxic
materials. Mucus is the principal airway
secretion with this function.
Airway mucus is a viscous solution with
defined physical and chemical properties
that enable it to be transported out of the
lungs by the ciliary motion of the ciliated
cells lining the airways. Thus airway mucus
is part ofthe mucociliary clearance mecha-
nism, also known as the mucociliary escala-
tor, that continuously sweeps trapped or
neutralized inhaled materials out ofthe air-
ways. This system also provides a vehicle
for the removal of alveolar macrophages,
the principal resident phagocytic cell in the
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lung, whose function is to ingest microor-
ganisms and other particulates that reach
the alveolar space. Alterations in mucus
properties can occur as a result of certain
disease states and exposure to inhaled toxic
compounds. As will be discussed, these
alterations can cause impaired pulmonary
clearance and a number ofpathologic con-
ditions leading to, and resulting from,
excessive mucus secretion.
The focus of this report is the role of
mucin in the pulmonary toxicology of air
pollutants. Included are sections describing
current concepts in mucin biology, i.e., its
biochemistry, biophysics, and histochemi-
cal properties, as well as its function in nor-
mal and pathophysiology. This is followed
by a review of effects on mucin biology
that are relevant to the pulmonary toxicol-
ogy ofinhaled pollutants.
Mucus Composition
The classic model of the airway mucocil-
iary system depicts mucus as a layer of
highly viscoelastic luminal secretions float-
ing on a layer offluid oflow viscosity (the
sol or periciliary fluid layer). Mucus from
healthy subjects is difficult to obtain
because, in the absence of trauma or dis-
ease, very little is produced by the lung
(1,2). Furthermore, even under carefully
controlled conditions normal mucus con-
tains significant quantities ofcellular debris
and airborne materials that confound
analyses. Largely due to the lack of suffi-
cient uncontaminated material available for
study, the composition of normal human
mucus is still uncertain (1,3). Analysis of
sputum obtained from diseased subjects,
normal secretions induced with hypertonic
saline and recovered secretions from laryn-
gectomized patients has yielded the consen-
sus that mucus is 95% water, 2%
glycoproteins, 1% proteins, 1% lipids, and
1% inorganic salts (1-4).
In contrast to normal airway secretions,
mucus produced in the airways of patients
with respiratory disease contains significant
amounts ofserum proteins. These proteins
are believed to be responsible for alterations
in the rheology ofairway secretions charac-
teristic ofsome pathologic conditions such
as bronchitis and bronchiectasis (3). Some
studies have suggested that at least part of
the lipid in intestinal mucus is in the form
of fatty acids covalently attached to glyco-
proteins (5,6). Airway glycoproteins, how-
ever, appear to contain small amounts of
fatty acids that are noncovalently associated
with hydrophobic regions of these mole-
cules (7). For an excellent discussion of
nonmucin proteins, antioxidants and other
organic constituents of airway mucus, the
reader is referred to a review by Hatch (8).
Water Content
Regulation of water content is crucial to
maintaining viscoelasticity that is optimal
'for the transfer of momentum from the
beating cilia ofthe airway epithelium to the
mucus blanket ofthe mucociliary clearance
system (1). A considerable fraction of the
water in mucus is bound to the macromol-
ecules or physically trapped inside the
interstices formed by dissolved glycopro-
teins (3). The amount ofwater in mucus is
determined by the availability of water in
the airway, which is tightly linked to the
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movement of the ions that make up the
inorganic salts found in mucus.
The source ofmucus water, and for that
matter all airwaywater, is vascular transuda-
tion from the blood (3). This transudation
results, in part, from the difference in
hydrostatic pressure between the vascular
bed and the airspace. However, the main
mechanism for moving water into the air-
way is provided by an osmotic gradient
established by the vectorial transport ofions
into the lumen carried out by the airway
epithelium. The tracheobronchial epithe-
lium secretes Cl- ions and absorbs Na+
ions. Under normal conditions, the amount
of Cl- ion secreted exceeds the amount of
Na+ ion taken in, establishing an ionic gra-
dient for net water secretion into the airway
(9). Water lost by evaporation during the
humidification ofinspired air also increases
the osmotic gradient and, thus, the water
movement into the airway lumen (10). The
ability to maintain the proper ionic compo-
sition of airway secretions is essential to
maintaining normal mucociliary clearance.
A defect in the mechanisms that regulate
ion balance in the airway lumen is the cen-
tral pathogenic feature ofcystic fibrosis (9).
Mucus Rheology
In terms ofboth normal and pathophysiol-
ogy, viscosity and elasticity are the most
important physical properties of mucus,
enabling it to be transported by ciliary
movement (11). The principal determinant
of the viscoelastic properties of mucus are
the mucous glycoproteins, or mucins.
Mucins are structural and secretary prod-
ucts ofall secretary epithelia, including the
airway epithelium. These glycoproteins are
normally found as a dissolved, entangled
network in mucus. When dissolved in puri-
fied form, mucins have been shown to form
a gel (12) and recreate the rheologic proper-
ties ofmucus (1). It is for these reasons that
mucins and the factors that affect their
structure and expression in health and dis-
ease have been extensively studied. Many
modern methodological approaches to the
study of the physicomechanical properties
of this complex material have been devel-
oped, as recently reviewed (13). They range
from models that seek to mathematically
describe and predict the behavior ofmucins
in solution (14), to two-phase gas-liquid
flow (15), magnetic rheometry (16), and
sinusoidal oscillation methods (17).
BiochemicalAnalysis
Mucins are complex and heterogeneous
molecules. They have been classified as
acidic and neutral species, depending on
their content of acidic groups, e.g., sulfate
or sialic acid. Based on their sensitivity to
neuraminidase, mucins have been further
grouped into sialic acid-containing and
sialic acid-free species (18). Acidic and
neutral glycoproteins can be distinguished
histochemicaly with Alcian blue-periodic
acid Schiff stain, with which acidic glyco-
proteins stain purple and neutral ones
appear magenta (19). This classification
scheme is useful in evaluating mucin histo-
chemical changes that occur in a variety of
disease processes. However, it is noted that
even "neutral" mucins contain sialic acid
and sulfate when analyzed chemically.
Mucins are polydisperse and highly gly-
cosylated molecules with molecular weights
varying from a few hundred thousand to
well over a million daltons (20). Mucin
polydispersity may be the result of varia-
tion in peptide size (21). The classic struc-
tural representation ofmucin is that ofthe
"bottle brush," which depicts hundreds of
carbohydrate chains attached to a peptide
core (22). Typical methodology for the
analysis of mucin (23) includes extraction
with 8 M urea (24,25) or a chaotropic
agent such as 6 M guanidinium chloride in
the presence of endogenous protease
inhibitors. After low-speed centrifugation
to remove insoluble material, mucins are
isolated in the void volume of an agarose
gel column and further purified by CsCl
density gradient centrifugation according
to their density. Characterization ofmucin
glycoproteins is accomplished by agarose-
polyacrylamide gel electrophoresis (26,27)
with silver staining and analytical ultracen-
trifugation (11,28). Electron microscopy is
also widely used for the analysis of the size
and architecture of mucin glycoproteins.
This technique has revealed that these mol-
ecules are flexible random coils with
lengths ranging from 0.2 to 5 pm (29-31),
although variations between studies exist,
apparently due to differences in sample
preparation (32). Sample handling and
preparation has a significant effect on the
integrity of mucins analyzed by other
methodologies as well. To isolate intact
mucins, the once standard high-shear
extraction methods and disulfide bond-
breaking reagents such as dithiothreitol are
now avoided (11).
MucinPeptides
Until recently, mucins were thought to
have relatively conserved amino acid
sequences (1). However, recent evidence
obtained using methodologies that preserve
the protein core of these glycoproteins, as
well as new gene sequence information,
suggests that there are multiple and poly-
disperse peptides, or apomucins (33,34).
Protease-sensitive, sparsely glycosylated
regions are found at both or one end ofthe
peptide and are rich in aspartate and cys-
teine (approximately 13 to 16 per region).
These cysteine residues form disulfide
bonds within and between peptides and
appear to dictate the folding of the assem-
bled mucins (1). The glycosylated regions
of mucin are protease-resistant segments
rich in serine and threonine residues linked
to carbohydrate chains (22).
Carbohydate Content
Approximately 80% of the weight of the
mucin molecule is carbohydrate (33), and
these covalently attached sugars confer
mucins with most of their heterogeneity
and structural complexity (22). These car-
bohydrates are arranged in chains, called
mucin type-glycans that include fucose,
galactose, N-acetylglucosamine, N-acetyl-
galactosamine, and N-acetylneuraminic
acid. Mucin type-glycans are linked to the
peptide at a serine or threonine residue by
N-acetylgalactosamine that is alkali-labile
(22,35). Reductive elimination frees the
mucin type-glycan from the peptide and
produces chains that range in size from 1
(N-acetylgalactosamine) to 20 carbohydrate
residues (36). In addition, mucin oligosac-
charide structures vary greatly with regard
to anomeric configuration and linkages.
For example, galactose can link to an adja-
cent sugar, either galactose, N-acetylglu-
cosamine, or N-acetylgalactosamine, in a
or ,B anomeric forms and in 1-3, 1-4, or
1-6 linkages. Mucin glycans can be classi-
fied into three groups ofincreasing acidity:
neutral, sialylated, and sulfated
(22,36-38). To date, over 100 mucin
oligosaccharides have been identified,




The lungs ofa typical healthy adult secrete
mucus at a rate of 0.1 to 0.3 ml/kg body
weight per day. Airway mucus is produced
and secreted by several different cell types.
Perhaps the most specialized cell for this
task is the goblet cell, found mainly scat-
tered among ciliated cells in the trachea
and, in fewer numbers, in the bronchi
(42). Goblet cells are the only example ofa
unicellular gland in mammals, their main
secretary product being mucin. As its name
implies, this is a vessel-shaped cell with an
expanded apical end that is filled with
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secretary granules. These granules are
secreted from the cell as the membrane sur-
rounding individual granules or coalesced
groups of granules fuses with the plasma
membrane, spilling their contents out ofthe
cell. Under certain stimuli, goblet cells are
capable of secreting all of their granules at
once (10,43).
Clara cells are the most prevalent cell
type found in the small airways and are
capable of differentiating into other cell
types of airway epithelium such as goblet
cells (44). Clara cells are known contribu-
tors to the sol, or periciliary, fluid layer and
are also the principal site of xenobiotic
metabolism in the lung (10). Serous cells
are another type of glycoprotein-secreting
cell. These cells mainly produce neutral gly-
coproteins which are found packaged-in dis-
tinct, electron-dense granules (45).
Interestingly, serous cells appear to secrete
N-glycosylated glycoproteins (46), a type of
glycoprotein related to, but distinct from,
the O-glycans. Serous cells are known to be
capable ofresponding to inhaled irritants by
undergoing a form ofmetaplasia to become
goblet cells (44,47).
Serous cells are arranged within the ter-
minal portion of the acini (an acinus is a
rounded exocrine secretary unit) ofsubmu-
cosal glands (43). The approximately 5000
submucosal glands found under the airway
epithelium between the trachea and the sub-
segmental bronchi are the major source of
mucus in the normal lung (10). The proxi-
mal terminus of the submucosal glands are
lined by mucus-secreting cells. These cells
are packed with confluent, electron-lucent
mucigen granules (43). Mucus acini in sub-
mucosal glands secrete mainly glycoprotein,
while serous acini also secrete antibacterial
compounds and antiproteases (48). The size
and number ofsubmucosal glands increases
when the airway is exposed to environmen-
tal irritants such as tobacco smoke (43).
Morphometric studies on airway goblet
cells and gland cells have shown that mucus
is secreted from these cells as droplets 1 to 2
pm in diameter (49). The droplets are
believed to be made up ofconcentrated gly-
coproteins, which in a matter of seconds
absorb several hundred fold theirweight and
volume in water drawn from the periciliary
fluid (50). As the glycoprotein droplets
swell, they begin to form plaques or "rafts"
of mucus that move over the periciliary
fluid. As the diameter of the airways
increases, these rafts coalesce into larger
islands ofmucus, to eventually form a sheet
ofmucus (51).
All secreted mucus is eventually trans-
ported out ofthe airways to the top ofthe
trachea, where it is swallowed. This process
is referred to as mucociliary function. It is
estimated that 10 ml ofmucus reaches the
top of the trachea in a healthy adult every
day (52). The mucus layer over the airway
epithelium is approximately 5 to 10 pm
thick and flows towards the trachea at a
rate of4.2 to 7 mm/min (53). Mucus flow
at the trachea is between 7 and 25
mm/min (10). Factors affecting the rate of
mucus flow include the thickness of the
periciliary fluid layer and the relative
humidity of inspired air, ciliary beat fre-
quency, gravity, and airflow. The contribu-
tion ofthese factors to the mucus flow will
be discussed next.
PerciliaryFluid
Surprisingly little is known about the peri-
ciliary fluid layer. It is believed to be an
epithelial cell exudate (54), 6 pm in depth
(10), having low viscosity and an ionic
content that is tightly maintained by the
movement of sodium and chloride by the
airway cells (55). The periciliary layer in
the distal airways and respiratory bronchi-
oles probably contains some surfactant and
other alveolar components (56). A phos-
pholipid layer appears to exist between the
periciliary fluid layer and the mucus sheet,
and may lower the surface tension between
the two layers (57). The thickness of the
periciliary fluid layer provides a low viscos-
ity medium between the cell surface and
the mucus layer in which the cilia can beat
andpropel the mucus blanket (44).
The relative humidity of inspired air
determines the rate of evaporation of fluid
from the mucus sheet. This effect is most
evident in the upper airways and the tra-
chea, where incomplete humidification of
inspired air is more likely (58). The effect
of airway evaporative loss on the depth of
the periciliary fluid layer is not known (10).
MucociliaryTransport
Another key determinant of the rate of
mucus flow is the ciliary beat frequency.
The movement ofsecreted mucus is carried
out by ciliated epithelial cells, the predomi-
nant cell type in the airways. Ciliated cells
in the airway are arranged in close juxtapo-
sition, forming a field of cilia, interrupted
by islands ofgoblet cells and mucus gland
openings (42). The cilia beat in a synchro-
nized, wavelike manner to propel the
mucus towards the trachea. Each ciliated
cell has 200 to 300 uniformly spaced cilia
about 6 pm in length (10). The cilia pro-
ject into the periciliary fluid, with only
their tips embedded in the mucus layer.
Each cilium is 0.25 pm in diameter and is
composed of an axoneme surrounded by a
special process of the plasma membrane
called the ciliary membrane (42,59). The
axoneme itselfis made up ofnine intercon-
nected doublets ofmicrotubules surround-
ing a pair of central microtubules. The
axoneme is anchored via the basal body to
the network ofmicrotubules ofthe cell cor-
tex. The basal body is composed of nine
interconnected triplet microtubules. Each
microtubule is made of protofilaments of
tubulin, a self-assembling cellular protein.
The microtubule doublets are linked to
each other via arms of dynein, a protein
with ATP-ase activity (43). The length of
the cilium ofthe respiratory epithelium is a
compromise between the bioenergetic
advantages offered by a longer dynein arm
and the required stiffness imparted by min-
imal length (56).
During ciliary movement, the axoneme
microtubule doublets.slide past each other.
The binding ofATP to dynein releases and
shortens the arm linking the doublets. As
the ATP is hydrolyzed, the linkage between
the doublets reforms at a more proximal site
(43). This cycle ofattachment and reattach-
ment of dynein arms between microtubule
doublets is repeated many times during each
ciliary beat. The beating ofgroups ofneigh-
boring cilia is synchronized into
"metachronal waves" as a result ofa similar-
ity in viscous forces experienced by the cilia
at a given location (44). A similar self-regu-
lating mechanism is responsible for enlisting
the number of beating cilia necessary to
keep mucus flowing at a steady rate. A given
patch of mucus is propelled by a group of
many cilia beating in a coordinated fashion.
As the movement of the cilium is slowed
down by the inertia of the slower-moving
mucus blanket, other cilia catch up with it
and transfer their energy to the mucus as
well. The net effect is that the slower the
mucus blanket moves over a given area of
the epithelium, the greater the number of
synchronized ciliapropelling it (44).
Due to its high glycoprotein content,
mucus behaves as a non-Newtonian fluid,
with elastic properties that cause it to tem-
porarily absorb energy by changing its
shape (56). The amount of time elapsed
between the deformation of mucus and its
recoil to its original shape is refered to as
the relaxation time, which has been mea-
sured to be approximately 30 sec for mucus
(60). Efficient transfer of energy from the
beating cilia to the viscoelastic mucus layer
requires that the ciliary beat frequency be
faster than the relaxation time (56). This
requirement is easily met, since typical cil-
iary beat frequencies range from 7
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cycles/sec in the peripheral airways to 25
cycles/sec in the trachea (61). This varia-
tion in ciliary beat frequency is reflected in
the above mentioned increased rate of
mucus flow that takes place in the trachea.
The surface area over which mucus flows in
the peripheral airways has been calculated
to be approximately 70 m2, compared to
0.6 m2 in the trachea (10). This means
that the proportionate volume of mucus
reaching the trachea is increased over 100-
fold with respect to the distal airways. The
higher tracheal ciliary beat frequencies are
needed to prevent mucus accumulation
and clogging ofthe airways.
Studies of the regulation of ciliary beat
frequency have suggested a dual control
mechanism. A direct neurohormonal effect
seems to be mediated by 3-adrenergic stim-
ulus and transduced via cAMP, with an
ultimate effect on the axoneme itself (62).
It has been proposed that cAMP and Ca2'
regulate ciliary beat frequency by regulating
the intracellular availability of ATP or its
access to the axoneme (63). In addition to
providing the chemical energy for the
movement of the cilia, ATP is one of sev-
eral purine nucleotides and nucleosides
demonstrated to provide luminal regula-
tory control of ciliary beat frequency via
specific purinergic receptors (64). A sec-
ond, possibly independent, effect is based
on mechanical stimulation of the cilia by
foreign particles or by mucus itself.
(56,62). Calcium flux experiments have
shown that mechanostimulation of ciliary
activity may involve the opening of cal-
cium channels and the elevation of intra-
cellular calcium concentrations (56). It is
clear that many stimuli of mucus secretion
also stimulate mucus transport, i.e.,
increase ciliary beat frequency. Whether
the ciliary response to these stimuli is sec-
ondary to the presence of increased
amounts of mucus on the cell or is inde-
pendent from it is an issue yet to be
resolved (56).
In addition to optimized ciliary beat
frequencies, efficient mucus mobilization
requires proper contact between the cilia
and the mucus blanket. Under normal con-
ditions, the cilia beat while completely
immersed in periciliary fluid, with only the
tips ofthe cilia coming in contact with the
mucus blanket (43). Each ciliary beat con-
sists of a propulsive stroke, a rest phase,
and a preparatory stroke. During the
propulsive stroke the cilium reaches its
maximum extension, causing the ciliary
crown to penetrate the mucus layer,
thereby transferring its momentum to it
(44,56). The rest phase may merely reflect
a metabolic recovery period or serve as a
reserve period that enables increased beat
frequency when needed (10). Ciliary
movement during the recovery period is
backwards and downwards, with a clock-
wise rotation in a plane parallel to the cell
surface (44,56). The combined effect of
the different phases ofthe ciliary beat is to
propel the mucus unidirectionaly, with
minimal energy spent repositioning the cil-
ium for the next stroke. The thickness of
the periciliary layer provides the critical dis-
tance that allows optimal ciliary contact
with the mucus layer above. The cilium
itselfappears to have a regulatory effect on
the depth of the periciliary fluid. If the
fluid is too deep, excess fluid may be swept
away by ciliary beating. When the layer is
too shallow, ciliary contact with the mucus
layer will be stronger, and this may stimu-
late ionic transport by the ciliated epithe-
lium which in turn results in increased
fluid secretion into the airway (56).
Several techniques for the measurement
ofmucus clearance rates have been devised
over the years, as recently reviewed by
Schlesinger (65). In their simplest form,
these methods involve monitoring the
movement of endogenous or artificial
markers (inhaled, blown in, or placed on
the airway) from the periphery toward cen-
tral areas of the respiratory tract. Artificial
markers commonly used include pollen,
Teflon disks, dyes, colored beads, and tech-
netium-99-radiolabeled iron particles.
Detection methods depend on the type of
marker used, but typically involve bron-
choscopy, serial sampling, or imaging with
a gamma camera. An elegantly simple
method for measuring mucus velocity in
the nose is the saccharine test, in which the
time elapsed before a subject is able to taste
a saccharine tablet placed in his nose is
measured (44,65).
Additional factors affecting mucociliary
transport include gravity and air flow (10).
Gravity can impair the efficiency of ciliary
activity significantly when the thickness of
the periciliary layer is greater than 10 pm
or when the fluid becomes less viscous due
to dilution. In large airways, turbulent air-
flow can also contribute to mucus clearance
(66). This is in fact the mechanical basis
for the cough reflex, the only alternative
mechanism for removing mucus from the
airways when mucociliary clearance is
impaired (10).
Mucin Biochemistry
Given that glycoproteins are responsible for
the physiologically relevant characteristics
of mucus, it has naturally followed that
research efforts directed at understanding
the metabolic and genetic aspects ofairway
mucus biology have focused on mucins.
Accordingly, the following section will
consist of a review of current mucin bio-
chemistry and molecular biology.
Mucin Genes andTranscription
Present understanding of the organization
and regulation of genes coding for mucin
peptides, or apomucins, is rudimentary, as
this field is very much in its developing
stages. Human tracheobronchial apomucin
genes have been mapped by Aubert and
colleagues to chromosomes 1 p15, 13, and
3 (33,67). In addition, a cystic fibrosis tra-
cheal apomucin gene has been mapped to
1lp13-11Ter (68). The presence ofmulti-
ple nucleotide sequence homologies
between chromosomes 11 and 13 have
hampered efforts to determine whether
there are multiple apomucin genes on
chromosome 11p15. However, at present,
at least two or three other chromosomes are
implicated as containing apomucin genes.
Only partial cDNA sequences of tra-
cheobronchial apomucins have been pub-
lished in the literature to date. Aubert and
co-workers screened a X-gtl 1 cDNA
library from human bronchial mucosa with
antibodies prepared against chemically deg-
lycosylated airway glycoproteins.
Immunohistochemical studies carried out
with these antisera showed specific labeling
ofgoblet and mucous glands that was lim-
ited to the perinuclear area and did not
include mucus granules, which contain the
highly glycosylated product (46). Upon
screening of the cDNA library with these
antisera, the nucleotide sequences of posi-
tive clones were examined (33). This work
has so far produced three families of
human tracheobronchial glycoprotein
genes, suggesting that human airway apo-
mucins are considerably more heteroge-
neous than once was thought. The first
family is described as consisting of repeti-
tive sequences of 8 and 16 amino acids.
This pattern ofmultiple repeated sequences
appears to be a characteristic of apomucin
genes. The second family contains two
clones with near identical amino and car-
boxy termini that share perfect homology
with 14 of a 22 amino acid stretch of a
human tracheobronchial apomucin previ-
ously published by a separate group (69).
Furthermore, this second family contains a
third clone that has sequences coding for
30 uninterrupted hydroxy amino acids.
The third family described by Aubert et al.
features hydrophobic and hydrophilic
regions arranged in alternating patterns. All
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of the tracheobronchial mucin cDNA
sequences described by Aubert's group
exhibit a repeated pattern consisting of a
domain ofhydrophilic amino acids flanked
by a histidine-rich sequence and a proline-
rich sequence. Presumably, these flanking
sequences code for nonglycosylated and
glycosylated regions of the peptide, respec-
tively. A partial sequence ofcanine tracheal
mucin cDNA has also been reported (70).
In addition to the extensive heterogene-
ity of apomucin genes, there is also much
variation at the transcriptional level.
Northern hybridization of mucosal epithe-
lium with mucin probes produces smears
instead of discreet bands, indicating that
there is extensive heterogeneity in the size
ofmucin mRNAs (71-74). On the basis of
sequence alignments and comparisons,
Aubert and colleagues have reported that
tracheobronchial mucin exons are relatively
small and may be derived from complex
alternative splicing (33,46). For detailed
information about mucin peptide genes, a
recent review article is available (34).
Glycosylation
Although mucin carbohydrate structure is
very heterogeneous, it can be understood
by noting some simple rules. For example,
there are three general domains to mucin
glycans: the core (not to be confused with
the peptide core), the backbone and the
periphery (20,74,75). The core is simply
the first two or three sugar residues that are
bound to the N-acetylgalactosamine at
reducing terminus.
The four major core structures found in
airway mucins are: Core 1, Gal(pl-3)Gal-
NAc(a-O)Ser/Thr; Core 2, Gal(P1-3)-
(GIcNAc(,I1-6)GaINAc(a-O)Ser/Thr;
Core 3, GlcNAc(P1-3)GalNAc(a-
O)Ser/Thr; Core 4, GlcNAc(01-3)
GlcNAc(P1-6)GalNAc(a-O)Ser/Thr.
The four backbone structures are: Type
1, Gal(I1-3)GlcNAc; Type 2,
Gal(p31-4)Glc-NAc; i antigen, GlcNAc-
(p1l-3)Gal; and I antigen, GlcNAc(Q1-3)-
(GlcNAc(PI-6) Gal (I-Step) and
GlcNAcf36Gal/GalNAc (I-Ma) (76).
The carbohydrate structures of the
peripherals are rather complex. For exam-
ple, sialic acid can link to C-3 or C-6 of
Gal and C-6 ofreducing terminal GalNAc
while sulfate has been identified at C-6 of
Gal (37,38).
Substitutions at the nonreducing termi-
nal type 1 chain can form blood group H,
Fucal-2Gal; B, Gal(al-3)Fuc(al-2)Gal;
A, GalNAc(al-3)Fuc(al-2)Gal; Lewis a
(Lea), Gal(P1-3)(Fuc(a1-A)GlcNAc; Lewis
b (Leb), Fuc(a1-2)Gal(P1-3)Fuc(a1-4)-
GlcNAc; and sialyl Lea, NeuAc(a2-3)-
Gal(P1-3)Fuc(a1-4)GlcNAc.
Substitutions at terminal type 2 chain
can form Lewis x (Lex), Gal(P1-4)Fuc-
(al-3)GlcNAc; Lewis y (LeY), Fuc(al-
2)Gal(P1-4)Fuc(a1-3)GlcNAc; and sialyl
Lex, NeuAc(a2-3)Gal(Q1-4)Fuc(al-3)-
GlcNAc in addition to blood groups H,
B, and A determinants. Fuc also links
al-2 to internal Gal, a structure recently
identified (38).
Thus, mucin glycans alone can vary
extensively in their overall structure, based
on the possible permutations of the cores
with the different backgrounds and possi-
ble peripheries. When one considers that
the mucus glycoproteins consist ofpeptide
chains covered in sections with this vastly
heterogeneous spectrum of mucin glycans,
it can be readily appreciated that these are
very large and highly complex molecules.
For further information about airway
mucin carbohydrate structures, several
comprehensive reviews have been pub-
lished (20,22,37,75).
As with any peptide, apomucin transla-
tion takes place in the rough endoplasmic
reticulum and involves the initiation, elon-
gation and termination of the peptide
product. The addition of the first sugar,
N-acetylgalactosamine, occurs at the cis-
Golgi compartment (77,78). Other glyco-
sylation steps as well as sulfation reactions
take place at various compartments of the
Golgi apparatus as demonstrated by cyto-
chemical, histochemrical and autoradi-
ographic approaches (79). Assembled
mucin glycoproteins are then packaged
inside vesicles formed from the Golgi
lamellae. Mucin secretary granules are
made up ofcoalesced vesicles, and migrate
towards the apical aspect of the cell where
they release their contents into the extra-
cellular environment (80).
Mucin oligosaccharide synthesis pro-
ceeds one at a time as catalyzed by glyco-
syltransferases, which transfer sugars from
nucleotide sugars to the acceptors.
Nucleotide sugars are generated in the
cytoplasm and then transported into the
Golgi lumen by specific transporters (81).
Assembly of mucin carbohydrate is sub-
jected to the control ofseveral factors (82),
including availability of nucleotide sugars
that serve as donors, relative activities of
the glycosyltransferases acting on the same
acceptor, the mucin peptide sequence,
presence of activator or inhibitor,
nucleotide sugar transporter (81), and pH
in the lumen ofGolgi apparatus (83). The
product formed in the preceding reaction
will then serve as the acceptor for subse-
quent glycosyltransferase reactions. In
other words, the assembly ofmucin carbo-
hydrates is not directed by a template, but
by various glycosyltransferase-catalyzed
reactions. The glycosyltransferases
involved in the assembly of mucin
oligosaccharides can be classified into the
chain-elongation and chain-termination
enzymes. The chain-elongation enzymes
generate the carbohydrate structures which
allow for continued growth of the carbo-
hydrate chains. This group of enzymes
includes mucin peptide:ctGalNAc trans-
ferase (77,84), I3Gal transferases (85-87),
and PGlcNAc transferases (88-90). On the
other hand, the carbohydrate structures
generated by the chain-termination
enzymes stop or limit further chain
growth. These enzymes include sialyltrans-
ferases (91), and blood groups A (92), B
(93), and H (94) enzymes. Ifsialic acid is
linked to the first sugar, i.e., GalNAc, the
product can not accept additional sugars.
Depending upon the sequence ofaddition
of these sugars as catalyzed by these two
groups of enzymes, mucin carbohydrate
chain length and structures can be very
heterogeneous. This phenomenon could
explain the tremendous microheterogene-
ity exhibited by mucin oligosaccharides.
When mucin synthesis nears completion,
sulfation of the oligosaccharides takes
place at the trans-Golgi membranes (81)
before mucin is packaged into the secre-
tory granules. Sulfotransferase-catalyzed
reactions utilize the sulfate donor, 3'-phos-
pho-5'-phosphoadenosylsulfate (PAPS).
PAPS is formed in cytoplasm from inor-
ganic sulfate, which is derived from serum
inorganic sulfate, or from sulfur-contain-
ing amino acids, by the consumption of
two molecules ofATP as sequentially cat-
alyzed by ATP sulfurylase and adenosine
5'-phosphosulfate kinase (95,96).
Glycoprotein Release
As reviewed by Verdugo, there have been
several recent advances in our understand-
ing of the complex processes that lead up
to the release ofmucins from the cell, and
the formation ofthe continuous mucus gel
that covers the airway epithelium (97).
The attachment ofa secretary granule con-
taining mucins in a condensed state to the
plasma membrane at the apical end of the
epithelial cell is the first step in mucin exo-
cytosis. The expansion ofa fusion pore on
the plasma membrane leads to increased
water and ionic permeability and release of
the granule contents into the airway. Until
relatively recently it was thought that
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membrane tension established by osmotic
swelling of the secretary granule was
responsible for the formation and widen-
ing of the pore. However, new evidence
has shown that pore formation precedes,
and can be uncoupled from, granule
swelling (97).
The explosive rate of swelling under-
gone by mucins upon exocytosis cannot be
accounted for by a simple osmotic process.
Moreover, condensed mucin granules fail
to decondense when placed in water free of
ions (98). These and other findings have
led to the "jack-in-the-box" model of gly-
coprotein exocytosis (97). This theory pro-
poses that glycoprotein exocytosis is the
result of rapid swelling of the glycoprotein
polymer inside the secretary granule. While
inside the granule, glycoproteins are in a
condensed state that is maintained by the
presence ofa shielding species, such as cal-
cium ion in the case of mucin. Increased
permeability due to pore formation and
widening results in the exchange ofcalcium
for sodium inside the granule. This causes
the mucin molecules to undergo a rapid
phase transition to a hydrated, decon-
densed state (i.e., to swell) and be released.
Once released, airway mucins serve as
the key rheologic assembly component of
airway mucus. As pointed out by Verdugo,
it is the ability ofmucins to form entangle-
ments rather than crosslinked networks
which allows mucus to expand in an uncon-
strained manner while absorbing water to
form the mucus gel. Determinants of
mucus hydration include water availability,
the concentration of ions and polycations,
and the pH ofthe airway liquid (97).
Physiologic and Pharmaco-
logic Control of Mucus
Release
Neurogenic Control
Basal production and release of airway
mucus in humans is believed to be sponta-
neous and independent ofenervation, since
neurotransmitter antagonists and vagotomy
have no effect on secretion (99).
Furthermore, tracheobronchial explants
continue to secrete mucus in vitro (3).
However, stimulation ofmucin production
above basal levels by submucosal glands is
clearly under autonomic control.
Parasympathetic control is evidenced by
studies showing that electrical stimulation
of the vagus nerve results in increased
mucus secretion by submucosal glands.
Vagal control of submucosal glands is
cholinergic, since it can be reproduced with
cholinergic agonists like pilocarpine and
blockedwith cholinergic antagonists such as
atropine (100).
There is also evidence of sympathetic
control of airway mucus secretion via beta
receptors (54). a and P adrenergic sympath-
omimetic agents have specific effects on sub-
mucosal glands. Mucus and serous cells are
stimulated through a receptors to secrete
mainly fluid and some glycoprotein. In con-
trast, specific P agonists target mucus cells to
release chiefly glycoprotein. This implies
that mucus composition is at least partly
under autonomic control, and is thus sus-
ceptible to pharmacologic intervention (3).
As reviewed by Phipps (3), airway mucus
secretion can also be stimulated via reflex
mechanisms. Both fluid and glycoprotein
secretion by submucosal glands can be
increased by mechanical and chemical irrita-
tion of the airway epithelium. Reflex-medi-
ated release of glycoprotein from
submucosal glands involves, but may not be
limited to, sympathetic and parasympathetic
enervation.
Humoral Control
A variety of bioactive peptides and lipids
also stimulate mucus secretion in the airways
under certain experimental conditions.
Histamine is effective in the cat and goose
trachea (100), but not human airways in
vitro (55), while substance P and kallidin
are stimuli ofthe dog and rat trachea (80).
ProstaglandinsAl, El, E2, FIa, and F2a are
also stimuli of tracheal mucin secretion
(80,101). The potent phospholipid inflam-
matory mediator platelet activating factor
also stimulates mucin secretion of tracheal
explants in vitro (102).
Mechanism ofGlycoprotein Release
Relatively little is known about the cellular
and biochemical mechanisms that mediate
the release ofglycoprotein in airway cells. As
reviewed by Spicer and Martinez, there is
evidence to suggest that the mechanisms are
similar to those of other exocrine glands
(80). Cyclic nucleotides stimulate mucin
release in rat tracheal explants, suggesting
their role in a signal transduction mecha-
nism. Similarly, the phosphodiesterase
inhibitor, theophiline, causes glycoprotein
secretion in human airways in vitro (100).
Calcium dependency, possibly with a role in
signal transduction, has also been demon-




The study of selective release of glyco-
protein from submucosal glands and
goblet cells in the airways is complicated
since both are present in airway tissue.
Recently, studies of goblet cells in tissue
culture have yielded insightful informa-
tion, as reviewed by Kim (103). While
stimulation of glycoprotein release from
submucosal glands is neurogenic, goblet
cells appear to be under local humoral
control (100). No efferent enervation
occurs above the level of the submucosal
glands of the airway (42). Furthermore,
direct neurogenic stimulation, such as
stimulation of the vagus nerve, does not
alter mucin release in the goblet cell
(77). Consistent with these findings,
many effective submucosal autonomic
agents that stimulate mucin release in
explants have no effect on goblet cells in
vitro. These include acetylcholine, nor-
epinephrine, and isoproterenol (100).
This contrast in the pharmacology of
mucin release by submucosal glands and
goblet cells seems to extend to pro-
inflammatory humoral mediators as well.
For example, prostaglandins E2 and F2a
have no effect on goblet cells in vitro, yet
they induce mucus secretion in animal
trachea (80,103).
Release of glycoproteins by goblet
cells in vitro can be stimulated by ATP,
proteases, or by physicochemical manip-
ulations, such as alteration in pH,
mechanical stress, and hypoosmolarity
(103). The response to ATP is receptor
mediated and specific. In contrast, gly-
coprotein release induced by physico-
chemical stimuli, such as pH changes, is
believed to be the result of damage of
the cell membrane. Hypoosmotic condi-
tions are analogous to mechanical stress
on the cell in that both types ofstimulus
seem to work through pressures exerted
on the cells. Similarly, the effect of mast
cell and neutrophil proteases (e.g., elas-
tase, chymase, and cathepsin G) may
also be nonspecific, being the result of
cleavage of membrane-bound glycopro-
teins as well as damage caused by hydrol-
ysis of cell membrane proteins
(103,104). For additional information
regarding mechanisms that control
mucus release, the reader is refered to an
excellent review by Lundgren and
Shelhamer (105).
Mucus in Lung Disease
Pathophysiologic changes involving airway
mucus are a feature of many pulmonary
diseases. These changes can be either quali-
tative, i.e., changes in mucus composition
or structure, or quantitative, i.e., changes
in the amount of mucus in the lung. A
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change in mucus composition could be due
to altered glycoprotein biosynthesis, elec-
trolyte transport, or water content.
Alternatively, structural modifications can
be the result of interactions between nor-
mal mucus and pathogens or reactive
chemicals.
Typically, quantitative changes in
mucus involve hypersecretion of airway
mucin. The pathogenesis of mucus hyper-
secretion in the airway was recently
reviewed (105). Hypersecretion can be due
to increased mucin biosynthesis and release
by goblet cells or submucosal glands, or to
increased numbers of mucin-secreting cells
brought about by faster cell division
(hyperplasia) or by differentiation of non-
secreting cells (metaplasia) (106,107).
Another mechanism leading to increased
mucus volume in the lung is leakage of
plasma components into the airspace as a
result of increased vascular permeability
(107). A brief review of pulmonary dis-
eases in which some of these underlying
mechanism contribute to the pathologic
role played by mucus now follows.
ChronicBronchitis
Chronic bronchitis is basically an inflam-
matory disease of the airways characterized
by persistent chronic cough with sputum
production. Most patients with chronic
bronchitis are smokers or ex-smokers (108).
Microbial and viral infections, as well as
urban and industrial air pollutants, are
believed to exacerbate the condition, but are
not likely initiators of bronchitis (106).
The pathologic hallmark of chronic bron-
chitis consists ofhypertrophy and hyperpla-
sia of submucosal glands, as well as
hyperplasia and metaplasia of goblet cells
(105,106). Mucus hypersecreted in chronic
bronchitis is apparently normal in composi-
tion, although it can contain a higher con-
tent of plasma components which may
inhibit ciliary activity (108,109). Mucus
from bronchitic patients is more viscous
during flare-ups ofthe disease. In addition,
persistent reductions in the rate ofmucocil-
iary clearance have been reported in
patients with chronic bronchitis (108).
CysticFibrosis
Cystic fibrosis is a disease that illustrates in
compelling terms the importance of
mucociliary clearance to normal lung func-
tion. The most common lethal genetic dis-
ease among Caucasians (9), cystic fibrosis is
characterized by a systemic defect in
exocrine gland secretion. Expression of the
disease varies considerably, but sweat and
mucus glands are involved most frequently.
The most serious manifestation of the dis-
ease is the retention within the airways of
abnormally viscous mucus (106). It is the
inability of the mucociliary system to
remove this thick mucus, along with
trapped microorganisms and debris, that
results in enlargement ofairway caliber and
persistent infection. Persistent infections
with Staphylococcus aureus and Pseudomonas
aeruginosa are characteristic ofcystic fibrosis
and lead to chronic inflammatory reactions
which are believed to be responsible for
much ofthe destruction oflung tissue that
is seen in patients afflicted with the disease
(106,110). The inflammatory response is
multistaged and complex, involving the
participation ofneutrophils, monocytes and
macrophages. Proteolytic destruction of
lung tissue by neutrophil-derived proteases
such as elastase is thought to be a principal
source of lung damage in cystic fibrosis
(110). Increased sulfation ofairway mucins
(24) and other high molecular weight gly-
coconjugates (111) has been reported.
However, the relationship between altered
sulfation of glycoconjugates to the basic
defect, mucus accumulation, and bacterial
colonization in cystic fibrosis patients
remains to be elucidated.
As reviewed by Welsh, the central path-
ogenic feature of cystic fibrosis is an alter-
ation in electrolyte transport by the airway
epithelium, which leads to insufficient
hydration of glycoproteins (9). Airway
epithelial cells secrete CF- into the airway
and absorb Na+ from the airway. CF- and
Na+ ions are first co-transported into the
basolateral side of the cell in an electrically
neutral process that allows intracellular
transport of CF against its concentration
gradient. This process is made possible by
the action of a Na+/K+ATPase, which
exports Na+ through the basolateral mem-
brane ofthe cell, thus keeping its intracellu-
lar concentration low. This ATPase activity
also moves K+ into the cell, which indi-
rectly contributes to a favorable gradient for
apical CF- secretion and Na+ absorption
through specific regulated channels. Many
neuropeptides (e.g., bradykinin), hormones
(e.g., aldosterone) and mediators
(prostaglandins) influence the permeability
ofthe CF- channel(s), apparently by increas-
ing cAMP levels in the cell (9).
Airway epithelial cells from cystic fibro-
sis patients secrete considerably less CF- ion
and absorb more Na+ through their apical
membrane than cells from normal subjects
(9,121). This is due, at least in part, to a
defective cAMP-regulated CF transport
channel (9,113). The putative gene
responsible for this defect was identified in
1989 (114-116). The gene coding for
"cystic fibrosis transmembrane conduc-
tance regulator" (CFTR) has a deletion of
3 base pairs corresponding to phenylala-
nine at residue 508. This single mutation
in CFTR accounts for 70% ofcystic fibro-
sis genes (116). The altered CFTR peptide
causes abnormal glycosylation of CFTR,
rendering its failure to be targeted to the
plasma membranes at 370C (117). This
targeting abnormality can be reversed at
270C (118). CFTR has been shown to be
a chloride channel (119); however, other
physiological functions ofCFTR remain to
be identified.
Asthma
Bronchial asthma is essentially a chronic
respiratory disease that manifests itself
intermittently as attacks ofdyspnea (short-
ness of breath) and wheezing caused by
bronchial spasms. Nearly all characteristics
of the disease such as its severity, course,
aggravating factors and frequency and
duration of attacks, vary widely among
patient. Most patients have a familial pre-
disposition to atopic disease. Several types
ofasthma are recognized based on apparent
etiologic factors. These include exercise
asthma, cold air asthma, and industrial
(chemically induced) asthma (106). 'While
the basic mechanism of the disease is still
poorly understood, all asthma attacks seem
to involve a predisposing airway hyperreac-
tivity and the release of a battery of
inflammatory mediators that cause
bronchoconstriction and mucus hyper-
secretion (105,106). A great deal of atten-
tion has been focused on the possible link
between air pollution and an alarming rise
in the number of cases of fatal asthma
attacks (120).
Gross pathology findings in the airways
of victims of fatal asthma attacks (status
asthmaticus) include the presence ofa tena-
cious mixture ofmucus, exudate, epithelial
cells, lymphocytes, and eosinophils (48).
Mucoid impactions in the airways of asth-
matics may be present even in the absence
of infection (121). Also evident are hyper-
plasia and hypertrophy of submucosal
glands and hypertrophy, hyperplasia, and
metaplasia ofgoblet cells in peripheral air-
ways (106). The same histologic changes
are reported in patients with stable asthma,
but to a lesser degree (122). Mucus plugs
and impaired mucociliary clearance may be
found even in patients with mild asthma or
during remission of the disease (123,124).
In addition to hypersecretion, changes in
mucus secretion in bronchial asthma
include increased permeability to serum
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constituents and altered water transport
into the airway (122).
Increased endothelial permeability is
believed to mediate the airway edema
observed in cases offatal asthma. Similarly,
increased epithelial permeability is likely to
be responsible for the leakage of serum
components into the airway, changes in the
periciliary fluid layer that can lead to inhi-
bition of ciliary function, and increased
mucus volume in the lung (109,122). In
addition, changes in water transport by the
airway epithelium, possibly mediated by
histamine, have been reported in experi-
mental asthma models and may also con-
tribute to these effects (122).
SputumAnlysis
Mucus samples are often obtained for clini-
cal analysis and diagnosis as expectorated
sputum. Sputum is a chemically unstable
mixture of mucus, saliva, surfactant, cells,
and plasma constituents that is not present
in the normal lung (109). A further com-
plication of inferences made from sputum
analysis is the need to distinguish between
purulent and nonpurulent sputum.
Purulent sputum is recovered from patients
with an overt or underlying infection and
usually has increased amounts ofglycopro-
tein, DNA, and a higher content ofplasma
constituents than nonpurulent sputum
(10.9). In spite ofthese limitations, sputum
samples can yield useful information about
pathologic changes involving mucus pro-
duction in disease. For instance, an increase
in the N-acetylneuraminic acid:fucose ratio
in the sputum is understood to reflect leak-
age ofplasma constituents into the airway,
which in turn, may indicate a relatively
more severe inflammatory reaction in the
airways. An elevated N-acetylneuraminic
acid:fucose ratio is observed in sputum
samples obtained from patients with
asthma; however, the absolute concentra-
tion of these compounds is low. This sug-
gests that plasma constituents contribute
significantly to the increased volume of
mucus present in asthmatic lungs. Sputum
obtained from bronchitis patients, on the
other hand, has high amounts ofN-acetyl-
neuraminic acid and fucose but the ratio is
normal, indicating that the increased
amount ofmucus produced in bronchitis is
mainly the result ofhypersecretion. In spu-
tum from patients with cystic fibrosis the
reverse is found, i.e., relatively normal
amounts of N-acetylneuraminic acid and
fucose but a high N-acetylneuraminic
acid:fucose ratio. This suggests that in cys-
tic fibrosis, there is an inflammatory
process that results in leakage of plasma
components into the airwaywithout hyper-
secretion ofmucus (109).
The DNA content ofsputum is a simi-
lar marker of the severity of lung inflam-
mation. Normal lung secretions and
nonpurulent bronchitis sputum do not
contain detectable amounts of DNA. In
contrast, purulent bronchitis sputum con-
tains detectable amounts of DNA, and
even nonpurulent cystic fibrosis sputum
contains significant quantities of DNA.
This finding may well attest to the relative
severity ofairway inflammation that occurs
in cystic fibrosis (109). Human recombi-
nant DNase has been examined as a possi-
ble therapeutic means to alleviate the
symptoms ofCF patients (125).
Morphologic Changes in Disease
Although hypertrophy of submucosal
glands is evident in both bronchitis and
asthma, a relatively greater increase in
mucus acini compared to serous acini is
seen to occur in bronchitis, but not
asthma, patients (48,126). Since the serous
acini ofsubmucosal glands secrete antibac-
terial and antiprotease compounds in addi-
tion to glycoprotein, the dilution of these
components by an increased volume of
mucus could result in diminished resistance
to both infection and proteolytic attack in
bronchitis (48).
The mechanism responsible for the
development of submucosal gland hyper-
trophy and hyperplasia in asthma and
bronchitis is presently unknown. However,
neutrophil-derived proteases such as elas-
tase have been implicated in goblet cell
hyperplasia, as reviewed (105,107). These
authors have also proposed a possible
mechanism wherein chemotactic lipid
mediators such as leukotriene B4 are
secreted by epithelial cells during the initial
stages ofairway inflammation. These medi-
ators could recruit neutrophils into the air-
way which could then release elastase,
causing goblet cell hyperplasia. In support
ofthis scenario is the finding that glucocor-
ticoids, which inhibit the synthesis oflipid
inflammatory mediators, can prevent gob-
let cell hyperplasia induced by neutrophil
products (127).
Effects of Air Pollutants on
Airway Mucus
Inhalation of a variety of ambient and
occupational air pollutants is known to
result in a number of untoward effects in
the lung. These include changes in pul-
monary function, diminished lung defense
and impaired mucociliary clearance, as well
as obstructive, inflammatory, and neoplas-
tic disease. These topics have been the sub-
jects of several excellent recent reviews
(128-132). This section will focus on spe-
cific effects of air pollutants on airway
mucus function, secretion, and biosynthe-
sis, as they pertain to the development of
pulmonary toxicology and disease.
Effects onMucociliaryFunction
Impairment of mucociliary function is a
consequence of exposure to a variety of air
pollutants. The effects of inhaled toxicants
on respiratory tract clearance mechanisms
have been reviewed by Schlesinger (65).
Essentially, mucociliary targets of inhaled
air pollutants are the ciliated epithelium,
the periciliary fluid, and the mucus layer.
In addition to the outright epithelial
desquamation or destruction of cilia
induced by high concentrations of SO2,
NO2 and 03 (133,134), ciliary activity in
the airway epithelium is susceptible to alter-
ation by toxic agents. Agents that impair
ciliary beat rate (i.e., induce ciliary dyskine-
sia or ciliostasis) include H2SO4 (135),
SO2, NO2, ammonia (136), wood dust,
cadmium (137), nickel, hairspray (138),
cigarette smoke (139), and formaldehyde
(140). Interestingly, Grose and colleagues
found that prior exposure to 03 diminishes
the ciliostatic effect ofH2SO4 in an ex vivo
system (135). The mechanism of action of
ciliostatic compounds can involve structural
damage of the cilium, as induced by NO2
(141), or altered energy metabolism caused
byheavy metals (65,138).
In spite of these findings, the relevance
ofthe ciliostatic effect ofinhaled pollutants
as a mechanism responsible for impaired
mucociliary activity is thrown into ques-
tion by two factors. First, it has been noted
that the dose oftoxicant required to induce
ciliostatic changes usually far exceeds that
required to produce a reduction in
mucociliary clearance (65,142). Second, a
study conducted by Battista and colleagues,
showed that 10% ofthe ciliated epithelium
in chicken trachea could carry out 30 to
50% of particle transport activity seen in
control animals, suggesting that ciliary
activity is present in large excess of that
needed for normal ciliary function (143).
Thus changes involving mucus production
and function may be more likely mecha-
nisms of the impaired mucociliary clear-
ance induced by inhaled toxicants (142).
PhysicochemicalAlterations
Another way in which an inhaled pollutant
can alter mucociliary clearance is by alter-
ing mucus rheology, either by interacting
with mucus constituents directly or by
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influencing its biosynthesis. An alteration
of mucus rheology, such as a decrease or
increase in viscosity, can diminish the effi-
ciency with which energy is transferred
from the beating cilia to the mucus blan-
ket. As presented by Holma (144) varia-
tions in mucus pH, such as those caused by
SO2 can have a profound effect on mucus
rheology. Although factors such as protein
concentration and ionic strength also come
into play, a reduction in pH generally
increases mucus viscosity (144).
Glycoproteins appear to be the principal
acid-reactive component in mucus, and, in
fact, have been demonstrated to be largely
responsible for the buffering capacity of
mucus (144).
Schlesinger (65) discusses chemical
cross-linking of glycoproteins as a mecha-
nism via which inhaled toxicants can alter
mucus viscosity. Exposure to formalde-
hyde, a compound known to form chemi-
cal cross-links in proteins and nucleic acids
(145), reportedly produces increased
mucus viscosity (146). Similarly, reduced
viscosity resulting from exposure to 03 is
proposed to be caused by a decrease in the
number of chemical cross-links (65,147).
However, Verdugo has recently argued that
the rheologic properties of mucus are
imparted not by cross-links between glyco-
protein moieties, but by networks ofentan-
glements between glycoprotein strands
(97). Thus, while formaldehyde may
indeed increase mucus viscosity by forming
cross-links, the reduction in mucus viscos-
ity may not be due to the destruction of
existing cross-links between glycoproteins.
BiosyntheticAlterations
Certain inhaled toxicants induce qualitative
changes in glycoprotein biosynthesis.
Exposure to H2SO4, SO2, or cigarette
smoke induces a shift in the type ofglyco-
protein secreted by the airway to produce a
relatively more acidic mucin (18,19,64).
This phenomenon is also seen in chronic
bronchitis and cystic fibrosis, where the
degree ofsulfation ofsecreted glycoproteins
is increased (24,91,148), suggesting that it
is an adaptive response to cellular injury. In
addition, elevation of the activities of sev-
eral glycosyltransferases has been observed
in airway epithelium ofS02jexposed dogs
and patients with chronic bronchitis
(149,150). With cigarette smoke, the
increase in acidic mucin seen in submu-
cosal glands and goblet cells is due to an
increase in sialic acid-containing mucins
(18). Normal rat tracheal epithelium pref-
erentially secretes neutral glycoprotein,
while in the peripheral airways there is a
bias for the production ofacidic glycopro-
tein. Acute exposure to cigarette smoke
abolishes these regional differences within
24 hr, resulting in dominance by a cell that
produces both acid and neutral glycopro-
tein throughout the rat respiratory tract.
Sustained exposure to cigarette smoke
eventually results in a population of cells
that produces only acidic glycoprotein
(18,148). Unlike goblet cell hyperplasia,
the change towards secretion of acidic
mucin is apparently not blocked by the
anti-inflammatory compound phenyl-
methyloxadiazole (18). Whether increased
secretion of acidic mucin is due to secre-
tion of molecules with a higher acid con-
tent or more molecules with acid moieties
is unclear (148). Interestingly, induction of
acid glycoprotein secretion was not
observed using 03 as a toxicant in recent
studies by Hotchkiss and associates, who
found an increase in both acid and neutral
glycoprotein in rat and primate nasal
epithelium (151,152). Whether this
reflects a difference in the response by nasal
and tracheobronchial epithelium or in the
nature ofthe stimulus is not clear.
Effects onCiliaryFluid
The depth of the periciliary fluid layer
largely determines the quality of the inter-
action between the cilia and the mucus
blanket over the airways above. Optimal
periciliary fluid depth and composition are
necessary for efficient transfer of energy
from the tips ofthe cilia to the mucus dur-
ing the propulsive stroke, and for the
recovery stroke to take place unimpaired
(56). Periciliary fluid depth and composi-
tion can be affected by compounds that
affect ion transport by the airway epithe-
lium or increase epithelial permeability to
serum components, which can affect
mucus rheology and secretion ofglycopro-
teins (19,65,153). For example, in vitro
exposure to 03 results in increased Na+ ion
permeability across guinea pig airway
epithelium (154), while 03 inhalation pro-
duces increased water and C1r ion secretion
in sheep tracheal explants in vitro (153).
Similarly, 03 inhalation causes increased
epithelial permeability to macromolecules
in humans (155). Foster et al. found that
increased secretion of airway fluid or an
alteration of epithelial permeability could
be responsible for the alterations in
mucociliary function that they reported in
humans exposed to 03 (156). Exposure to
NO2 caused increased mucosal permeabil-
ity to large protein molecules in guinea pig
lungs (19). Increased epithelial permeabil-
ity to water and serum components is also
a feature of the pathology ofcystic fibrosis
and asthma (see preceding section).
Mechanisms ofHypersecretion
Mucus hypersecretion is an important part
of the sequelae induced by a number of
toxic insults to the lung. Possible mecha-
nisms of hypersecretion include increased
release of existing glycoprotein stores,
hypertrophy of submucosal glands, hyper-
plasia of goblet cells, metaplasia of non-
secreting cells into goblet cells, and an
altered rate ofmucin biosynthesis by goblet
cells or cells in the submucosal glands.
Inhalation of some toxic compounds
produces acute mucus secretion into the
airways. For example, NH3, (54), and 03
(19,153) induce glycoprotein discharge
from glycoprotein-secreting cells in the air-
ways. Exposure to acidic and alkaline
media also stimulate mucin release, albeit
secondary to cell membrane damage (157).
Similarly, inhalation ofdusts (e.g., charcoal
or barium sulfate) provokes release of
mucus from cat tracheal explants via a neu-
rogenic reflex pathway as well as a direct
stimulation of the mucosa (19). An
increase in tracheal gland sensitivity to
cholinergic stimulation has been reported
in ferrets exposed to 03 (158). Both myeli-
nated and unmyelinated (C-fibers) neu-
ronal pathways may be involved in the
discharge of mucus in the airway
(3,64,105). Eicosanoids such as
leukotrienes C4 and D4 and hydroxye-
icosatetraenoic acids, have also been shown
to mediate glycoprotein release from
human airway explants (159,160), and
may be involved in mucus secretion in
response to toxicant exposure (153). A
study by Jones et al. showed that acute
exposure of rats to cigarette smoke causes
extensive degranulation of mucus-secreting
cells, to the point that there is a transient
decrease in the number of cells staining
positive for glycoprotein content in the air-
ways (148). In the same study, the anti-
inflammatory phenylmethyloxadiazole did
not prevent tobacco smoke-induced dis-
charge of mucus-secreting cells. However,
in a similar study the same drug was shown
to be effective in preventing an increase in
the basal rate of mucin discharge induced
by tobacco smoke, possibly reflecting a dif-
ference in the time ofadministration ofthe
drug between these studies (161). The bal-
ance between glycoprotein synthesis and
release in secretary cells is reportedly
altered as a result of chronic inhalation of
tobacco smoke or SO2. This is evidenced
by a decrease in the number ofintracellular
glycoprotein granules in exposed cells, sug-
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gesting a higher rate of secretion of glyco-
protein granules relative to their storage
time inside the cell (80,148). Work by
Mariassy and colleagues has shown that 03
exposure can affect developmental changes
in the respiratory epithelium ofpostnatally
exposed lambs. Their studies demonstrate
that the decreased secretion of total and
sulfated glycoproteins that normally
accompanies maturation is retarded in 03-
exposed lambs, possibly leading to
impaired mucociliary function in these ani-
mals (162).
Increases in the number of airway
mucin-secreting cells can be induced by
inhalation of S02 (163), 03 (153), C12
(164), NO2 (165), or cigarette smoke
(166). SO2 and tobacco smoke-induced
hyperplasia have been studied as animal
models ofbronchitis. As reviewed by Spicer
and Martinez (80) and Abraham (19), sub-
mucosal gland cell and goblet cell hyperpla-
sia is readily apparent in the airways ofdogs
and rats chronically exposed to SO2. The
response ofthe goblet cell population in the
bronchi and bronchioles ofdogs exposed to
S02 is characterized by an increase in both
size and number (163). The expansion of
the goblet cells population is partially due
to metaplasia of other epithelial cell types
into gobletlike cells with enhanced mucus-
secreting capabilities (80). Submucosal
gland hypertrophy is apparently also due to
both increased replication rate and a meta-
plastic change of serous cells into mucus
cells (73,80). SO2 inhalation in dogs has
also been shown to cause elevated glycosyl-
transferase activities in the homogenates of
tracheobronchial epithelia, although it was
not possible to determine whether this was
merely a reflection ofthe histologic changes
also observed in these animals (150). A
recent study suggested that there is an
induction in mucin mRNA levels in the air-
ways of rats chronically exposed to SO2
(73). These results suggest that chronic
exposure of animals to SO2 enhances the
expression ofboth mucin and glycosyltrans-
ferase genes, resulting in hyperproduction
ofmucins.
Exposure to cigarette smoke also pro-
duces submucosal gland hypertrophy, gob-
let cell hyperplasia, and evidence of
serous-to-mucus cell metaplasia
(73,161,166). Tobacco smoke-induced
hyperplasia of secretary cells can occur
within hours of a single exposure and may
also involve basal cells (148). Metaplastic
changes in the airways of rats exposed to
cigarette smoke are evidenced by increased
rates ofmitosis among basal cells and serous
cells but not mucus cells (73). Tobacco
smoke-induced secretary cell hyperplasia in
rats can be inhibited with indomethacin
and steroidal anti-inflammatory drugs (e.g.,
dexamethasone, hydrocortisone), suggesting
that cyclooxygenase products are involved
(166). Mucolytic drugs such as N-acetyl-
cysteine are also inhibitors ofthe hyperplas-
tic response, perhaps by preventing
glutathione depletion in cigarette smoke-
exposed cells (166,167).
03 exposure also induces hypertrophy of
submucosal glands and hyperplasia of gob-
let cells (153). In this study, the morpho-
logic changes induced in the airways of
sheep by chronic 03 inhalation were corre-
lated with decreased glycoprotein and
increased water secretion. However,
increased glycoprotein secretion with con-
tinued water secretion was observed follow-
ing a period of recovery after exposure,
suggesting that the initial decrease in glyco-
protein secretion was due to depletion of
mucin stores (153). Similar kinetics, i.e.,
decreased glycoprotein secretion followed
by a rebound to increased secretion, was
seen in the tracheal explants ofrats exposed
to 03 in vivo (168).
It has been proposed that metaplasia
may play a larger role in toxicant-induced
hypersecretion than previously thought
(73,151). Evidence for this hypothesis is
based on studies showing increased num-
bers ofgoblet cell in areas ofthe lung where
they are normally scarce or absent, such as
the lung periphery (169), and an increase in
the population of mucus cells without an
apparent change in the mitotic rate ofthese
cells (170). Hotchkiss and associates have
demonstrated similar evidence of metaplas-
tic changes responsible for the increased
number of goblet cells in nasal epithelium
from rats exposed to 03 (151).
The possible role of inflammatory cell-
derived proteases such as elastase in the
development of metaplastic changes in the
airway induced by tobacco smoke or SO2
was recently reviewed by Jany and
Basbaum (73) and Lundgren et al.
(105,107). A study by Christensen et al.
(171) showed that a single dose ofpancre-
atic elastase causes an apparently irre-
versible goblet cell metaplasia in guinea
pigs. In a more recent study, the steroidal
anti-inflammatory drug dexamethasone
was effective in inhibiting neutrophil elas-
tase-induced goblet cell hyperplasia in rat
trachea, suggesting the involvement oflipid
mediators (127). Supporting this scenario
is the finding that prostaglandin E1 induces
increased numbers of mucus cells, without
preceding DNA synthesis, in the airways of
mice, a process apparently mediated
through cAMP since the analog dibutyryl
cAMP had the same effect (170). These
findings are intriguing in light ofstudies by
Koren and colleagues, which showed that
03 inhalation produces neutrophil infiltra-
tion into the airways, as well as increased
levels of eicosanoids and neutrophil-
derived elastase in bronchoalveolar lavage
fluid from human subjects (172).
Interestingly, no increase in elastase activity
was found in this study. The authors sug-
gest that this is possibly due to inactivation
of elastase activity by endogenous antipro-
teases such as x-l-antitrypsin (173), and
also that microfocal secretion by neu-
trophils could permit some elastase to
escape antiproteases (172,174). Tobacco
smoke exposure may also inhibit endoge-
nous antiproteases in the airway (175).
Summary and Conclusions
Airway mucus is a glycoprotein-rich mix-
ture secreted from the airways. It serves as a
dynamic, replenishable barrier against
inhaled particulate and gaseous contami-
nants in the lung. Vital to the role of
mucus as a component of both lung
defense and pathology are its viscosity and
elasticity which, under normal conditions,
permit mucus to act as an efficient "bio-
logic conveyor belt," removing trapped and
dissolved materials that enter the lung with
inspired air. These rheologic properties of
airway mucus are imparted by mucous gly-
coproteins synthesized and released by spe-
cialized cells in the airways.
Mucins are complex, heavily glycosy-
lated macromolecules whose biosynthesis
and secretion appear to be under close reg-
ulatory control, yet able to respond quanti-
tatively and qualitatively to alterations in
lung homeostasis, such as those resulting
from respiratory disease or inhalation of
toxic materials. An example of such a
biosynthetic response is the increased secre-
tion ofacidic glycoproteins seen in patients
with chronic bronchitis or cystic fibrosis,
and in animals exposed to cigarette smoke,
SO2 or H2SO4. Since changes in the pH of
mucus are associated with alterations in its
rheology, it is tempting to speculate that
increased mucus acidity is behind the
increase in mucus viscosity and reduced
mucociliary clearance that are also associ-
ated with these diseases and exposures.
The finding of changes in mucus pH
are also intriguing in light of the fact that
Holma (144) has suggested a link between
inflammatory airway diseases such as
asthma and alterations in the pH ofmucus
in the airway resulting from inhalation of
acid aerosols. Individuals producing mucus
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with low pH or low buffering capacity,
e.g., some asthmatics and smokers, may
have an elevated risk for developing unto-
ward respiratory sequelae with exposure to
acid aerosols. In addition to alterations in
mucus rheology, acidification of mucus
may lead to increased epithelial permeabil-
ity, and could therefore be a mechanism
leading to the airway edema seen with
asthma (144).
Increased epithelial and endothelial per-
meability to serum constituents is a hall-
mark of inflammation in any tissue, and a
pathologic feature of cystic fibrosis and
asthma (106). Leakage of serum proteins
and fluid is also thought to produce
changes in mucus rheology and affect the
periciliary fluid layer. One possible effect of
these alterations is impaired mucociliary
transport (65). Another consequence of
the presence of serum components in the
airway is the propagation of inflammatory
reactions that could potentially involve
dozens of known inflammatory mediators
and cytokines.
The eicosanoids are one class ofinflam-
matory mediators strongly suspected of
being involved in the pulmonary response
to toxic insult, possibly including those
affecting mucus physiology. These oxidized
derivatives of arachidonic acid are pro-
duced in response to a wide variety ofcel-
lular perturbations by a myriad of cell
types, apparently each able to produce a
characteristic spectrum of these com-
pounds. Eicosanoids such as leukotrienes
C4 and D4 and hydroxyeicosatetraenoic
acids, as well as the related lipid inflamma-
tory mediator platelet activating factor, are
known stimuli of glycoprotein release
(102,159,160) whose levels have been
shown to increase in cells exposed to 03
(176,177). In addition, bronchoalveolar
lavage fluid from subjects exposed to 03
contains elevated levels of various
eicosanoids (172). Thus, it is possible that
these bioactive lipids act as mucus secreta-
gogues in response to toxicant inhalation.
An equally important role ofeicosanoids
may be to signal the recruitment of
immune cells into the airways during the
early stages of inflammation. Inhalation of
some pollutants, e.g., 03, causes the recruit-
ment of neutrophils into the airways.
Similarly, increased numbers of lympho-
cytes and eosinophils are found in airway
secretions of asthmatics (106). Several
eicosanoids, most notably leukotriene B4,
are potent chemotaxins for neutrophils
(107,127), while platelet activating factor
administration produces neutrophil and
eosinophil infiltration into the airways
(102). These effects are relevant to the role
of mucus in the toxicology ofinhaled toxi-
cants vis-a-vis reports demonstrating mor-
phologic changes induced by mast cell and
neutrophil proteases.
The development of hyperplasia and
metaplasia of glycoprotein-secreting airway
tissues is a phenomenon that certain respi-
ratory diseases and inhaled toxicants have in
common. The hypertrophy of submucosal
glands and hyperplasia of goblet cells seen
in bronchitis, cystic fibrosis, and asthma is
also induced by inhalation of 03, SO2,and
tobacco smoke. Increased secretary capacity
is the major mechanism responsible for
mucus hypersecretion in the lung, and it is
likely a cause of increased mucus volumes
produced in response to chronic toxicant
inhalation.
The mechanism by which hyperplastic
and metaplastic changes are induced in the
lung are unknown. However, there is grow-
ing evidence that implicates the cationic
protease elastase in these responses
(107,127). Direct instillation of elastase is
known to produce goblet cell hyperplasia in
the lungs of rodents. In addition, airway
secretions from cystic fibrosis patients and
subjects exposed to 03 contain elevated lev-
els ofelastase which, ifactive, could partici-
pate in the generation of morphologic
changes leading to hyperplasia and mucus
hypersecretion in the airway (104,172).
The fact that hyperplasia induced by neu-
trophil-derived products in rats can be
inhibited by steroidal antiinflammatory
agents suggests that, here too, lipid inflam-
matory compounds such as eicosanoids
could act as mediators of pathologic
changes induced by inhaled pollutants.
Recently, much attention has been
placed on the role ofmetaplasia in morpho-
logic changes leading to hypersecretion in
disease states and as a consequence of toxic
insults (73,151). One hypothesis is that the
increase in numbers ofmucin-secreting cells
in disease or following toxicant inhalation is
an adaptive response to airway injurylargely
involving differentiation of nonsecreting
cells. Evidence supporting this notion is
based on histochemical findings of
increased goblet cell populations in areas of
the lung where they are normally rare and
in the absence ofchanges in the mitotic rate
ofcells in the airway. Preliminary work also
indicates that exposure of rats to SO2 can
result in mucin gene expression changes
that presumably would be required for non-
secreting cells to transform into mucin-
secreting cells (73).
As reviewed in this report, the targets of
toxicants on mucus biochemistry and phys-
iology are numerous, and it is certain that
new ones will be identified as a result of
ongoing research. The significance ofthese
alterations of mucus biology to human
health is less clear, as the effect ofenviron-
mentally relevant concentrations of pollu-
tants on acute and chronic mucus
hypersecretion needs to be determined. A
prominent exception is cigarette smoke, for
which ample epidemiologic evidence
demonstrating the relationship between
tobacco smoke-induced alterations in air-
way morphology, mucus hypersecretion
and chronic bronchitis already exists. In
addition, a 5-year epidemiologic study
examining respiratory effects in nonsmok-
ers found a strong correlation between per-
sistent cough and phlegm production and
long-term residence in an area with high
ambient SO2 levels (178). In view ofthese
findings, it seems particularly important to
determine whether pollutant-induced
mucus hypersecretion contributes to the
alarming rise in the number of asthma
deaths that has been reported in recent
years (120).
Many other important issues surround-
ing the role of mucus in the pulmonary
toxicology of inhaled pollutants remain
unresolved. A few are listed below.
One basic question involves whether
mucin gene expression can truly be
induced by toxicant exposure. Ifso, is this
induction part ofa metaplastic response or
independent from it? What are the effects
oftoxicants on the post-translational modi-
fication of the mucin peptide, such as gly-
cosylation and sulfation steps? Both the
qualitative and quantitative changes need
to be documented.
Our understanding ofmucus biophysics
also needs improvement. What is the true
composition and function of periciliary
fluid? What are the roles of other mucus
components, such as surfactants and pro-
teoglycans, in the maintenance ofthe rheo-
logical properties of mucus under normal
andpathological conditions?
The role of inflammatory mediators in
the generation and progression of inflam-
matory processes in the lung is one of the
most exciting and promising areas ofinves-
tigation in lung biology and pulmonary
medicine. What mediators are involved in
mucus hypersecretion induced by toxicant
inhalation?
For practical reasons most experimental
exposures to inhaled pollutants are acute
and at high dose. What are the effects of
chronic exposures to the more relevant low
doses? Similarly, what are the effects of
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exposure to low levels of multiple pollu-
tants?
In summary, essentially all aspects of
lung pathophysiology involving toxicant-
induced alterations in mucus structure and
function can be viewed in the context ofthe
role ofmucus in a stereotypical, generalized
response of the lung to cellular injury.
Based on our current understanding oflung
physiology, it is clear that the lung can
secrete mucus in response to perceived envi-
ronmental challenges such as irritation of
the airway mucosa. This response can be
described as graded in that it seems to be
proportional to the magnitude ofthe stimu-
lus and its duration. Thus a minor or brief
irritant exposure may produce a localized
and transient discharge of mucus from
existing stores in a section ofthe lung, while
a stronger or chronic irritation may result in
a full-blown response involving a long-last-
ing or permanent increase in the secretary
capacity ofthe lung as a whole. One teleo-
logic explanation ofthis response is that it is
an effort by the lung to neutralize and
remove the offending stimulus to minimize
tissue injury. In this light, it is somewhat
ironic that this protective mechanism can
itself be both a target of inhaled pollutants
and a potential source ofinjury to the lung.
From a pulmonary health point ofview, the
distinction between injury resulting from
effects of the toxicant on mucus biochem-
istry and physiology and that resulting from
the adaptive secretary response to the toxi-
cant maywell be academic.
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